Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24

Piramal Pharma’s Ahmedabad facility completes USFDA PAI

Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr

Piramal Pharma has reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024

Piramal Pharma launches new campaign for 'Polycrol' with Brand Ambassador Jisshu Sengupta

the campaign emphasizes the brand's reliability and effectiveness in providing timely relief

Piramal Pharma forays into men's grooming market in India with the launch of BOHEM

Piramal Pharma gets Form 483 with 2 observations from USFDA for Lexington, USA facility

The observations do not pose any risk to site's compliance standards or its business continuity

Piramal Pharma launches new concentration of Zinc Sulfate for Injection in U.S.

The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio

Piramal Pharma Solutions commissions ADC manufacturing expansion in Scotland

The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant

Piramal Pharma launches in-vitro biology capabilities at Ahmedabad discovery services site

Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening

USFDA inspection at Piramal Pharma’s Bethlehem facility